|Grant Affiliation:||Ho: Ibalizumab for HIV Prevention|
|Strategy:||Prophylactic neutralizing Ab|
|Study Type:||Antibody Screening|
|Study Start Date:||2009-12-16|
|Study Made Public:||2010-06-22|
Assessment of ibalizumab neutralization potency and breadth
CAVD 309 is an immunogenicity study to assess the potency and breadth of the monoclonal antibody, Ibalizumab, against a diverse Env-pseudotype panel.
Sign in to see full information about this study and to download study data.
No non-integrated data is available for this study.